TELO TELO
Company Profile ↓Company Overview
TELO (TELO) is a publicly traded company listed on with a market capitalization of $40.57M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -32.95% |
| 6 Months: | +0.00% |
| 3 Months: | -11.28% |
| 1 Month: | -4.84% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 38.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | 2.19M | 5.07M | 1.15M | 2.13M | 1.04M |
| Operating Income | - | - | - | - | 1.92M | - | - | - | -2.19M | -5.07M | -1.15M | -2.13M | -1.04M |
| EBITDA | - | - | - | - | - | - | - | - | -2.18M | -5.07M | -1.10M | -2.06M | -989.69K |
| Interest Expense | - | - | - | - | - | - | - | - | 46 | 1.34K | 0 | -1.39K | 1.25K |
| Pretax Income | - | - | - | - | - | - | - | - | -2.18M | -5.07M | -1.10M | -2.06M | -990.95K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -482.94K | -1.55M | -1.71M | -9.33M | -6.25M | -1.39M | -5.99M | - | -2.18M | -5.07M | -1.10M | -2.06M | -990.95K |
| Diluted EPS | -0.02 | -0.06 | -0.06 | - | -0.23 | 0.05 | -0.20 | - | -0.07 | -0.17 | -0.03 | - | -0.03 |
| R&D Expense | 440.33K | 667.63K | 262.56K | - | 804.02K | 594.80K | 627.43K | - | 337.00K | 42.84K | 759.52K | - | 467.80K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 854.15K | 3.94M | 12.24M | 10.54M |
| Operating Income | -854.15K | -3.94M | -12.24M | -10.54M |
| EBITDA | -854.15K | -11.43M | -12.19M | -10.41M |
| Interest Expense | 0 | 1.64M | 4.34M | 0 |
| Pretax Income | -854.15K | -13.07M | -16.53M | -10.41M |
| Tax Provision | - | - | - | - |
| Net Income | -854.15K | -13.07M | -16.53M | -10.41M |
| Diluted EPS | -0.03 | -0.44 | -0.56 | -0.33 |
| R&D Expense | 833.21K | 1.57M | 2.24M | 2.44M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 48.73K | 4.77M | 1.32M | 7.34M |
| Current Assets | - | 48.73K | 435.23K | 1.32M | 7.34M |
| Cash & Equivalents | - | 1.42K | 1.23K | 1.27M | 7.29M |
| Inventory | - | - | - | - | - |
| Receivables | - | 0 | 130.00K | 0 | - |
| Total Liabilities | - | 986.01K | 1.34M | 680.97K | 1.43M |
| Current Liabilities | - | 986.01K | 1.34M | 680.97K | 1.43M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | 101.00K | - | - |
| Total Equity | - | -937.28K | 3.44M | 643.04K | 5.91M |
| Shares Outstanding | - | 29.61M | 29.61M | 29.76M | 34.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -468.66K | -3.86M | -5.07M | -3.69M |
| Investing Cash Flow | - | - | - | - | - |
| Financing Cash Flow | - | 470.08K | 3.86M | 6.34M | 9.71M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | -468.66K | -3.86M | -5.07M | -3.69M |
| Net Change in Cash | - | 1.42K | -188 | 1.26M | 6.02M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 91.1% | -380.2% | -2,571.0% | -176.1% |
| ROCE % | 91.1% | -114.7% | -1,903.8% | -178.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TELO
Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical Type 2 Diabetes Model
Insulin Resistance Was Normalized Following 14 Days of Treatment, Supporting Restoration of Glucose Metabolism and Insulin Sensitivity and Further Validating Telomir-Zn's Metal-Homeostasis Mechanism Across Multiple Disease Models. MIAMI, FL…
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Study Published in Advances in Redox Research Demonstrated Dose-Dependent Survival Improvement, Reduced Hepatic Copper Burden, Improved Liver Biomarkers, and Reduced Tissue Degeneration in a Preclinical Wilson's Disease Model. MIAMI, FL / A…
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Company Plans to Initiate First-in-Human Phase 1/2 Trial in 1H 2026, Anchored by a Leading U.S. Academic Medical Center. MIAMI, FL / ACCESS Newswire / April 30, 2026 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"),…
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Transaction establishes global ownership rights of lead program and includes initial capital funding with additional optional milestone-based capital support aligned with key clinical milestones. MIAMI, FL / ACCESS Newswire / April 24, 2026…
Telo Genomics Announces Study with University of Athens to Advance Next-Generation MRD Risk Stratification in Multiple Myeloma
Clinical Trial Seeks to Validate Novel Blood-Based Assay that Predicts Relapse Risk by Analyzing the Biologic Behavior of Remaining Cancer Cells, Addressing Critical Gaps in Current Minimal Residual Disease (MRD) TestingVancouver, British C…
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS Newswire / March 31, 2026 /Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("T…
TELO — Frequently Asked Questions
What is the current share price of TELO?
As of 2026-08-05 17:25 PDT, TELO trades at $1.18 on NASDAQ/NYSE. Its 52-week range is $0.92 to $1.93.
What is the market capitalisation of TELO?
TELO has a market capitalisation of $40.57M on NASDAQ/NYSE.
What is the P/E ratio of TELO?
TELO trades at a trailing price-to-earnings (P/E) ratio of -3.58. Its price-to-book (P/B) ratio is 6.86.
Is TELO a good stock to buy?
This page provides a data-driven analysis of TELO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.